NextCure Inc
Company Profile
Business description
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer’s disease.
Contact
9000 Virginia Manor Road
Suite 200
BeltsvilleMD20705
USAT: +1 240 399-4900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
43
Stocks News & Analysis
stocks
Weekly earnings wrap: Last week’s winners & losers
stocks
Alphabet earnings: Continued momentum on cloud and search as capital expenses set to mount
stocks
Eli Lilly earnings: Revenue increases reflect global demand for oral obesity therapies
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,954.60 | 104.20 | -1.15% |
| CAC 40 | 8,265.41 | 3.25 | 0.04% |
| DAX 40 | 24,635.40 | 144.34 | 0.59% |
| Dow JONES (US) | 49,709.54 | 800.82 | 1.64% |
| FTSE 100 | 10,354.51 | 45.29 | 0.44% |
| HKSE | 26,559.95 | 325.29 | -1.21% |
| NASDAQ | 22,722.14 | 181.55 | 0.81% |
| Nikkei 225 | 54,253.68 | 435.64 | 0.81% |
| NZX 50 Index | 13,444.02 | 23.27 | -0.17% |
| S&P 500 | 6,869.73 | 71.33 | 1.05% |
| S&P/ASX 200 | 8,708.80 | 96.70 | -1.10% |
| SSE Composite Index | 4,065.58 | 10.33 | -0.25% |